Evidence map›Paper›PMID 37768422›Full record

ArticleDoklady. Biochemistry and biophysics2023

Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.

M R Yanova, A P Zhiyanov, I D Antipenko, S A Slobodov, E V Stepanova

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M R YanovaFaculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia. myanova@hse.ru.
A P ZhiyanovFaculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia.
I D AntipenkoFaculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia.
S A SlobodovFaculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia.
E V StepanovaFaculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia.
National Research University Higher School of Economics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine monophosphate (dFdCMP), one of the intracellular forms of phosphorylated gemcitabine, determines its antitumor activity. A pharmaco-molecular model for determining relative gemcitabine monophosphate level based on the assessment of the activity of ENT1 and ENT2 channels as well as dCK and CDA enzymes in tumor tissue was developed. Relative gemcitabine monophosphate level is a more relevant predictive factor of gemcitabine resistance of bladder cancer as compared with the expression of individual markers related to dFdCMP formation.

Indexed as

GemcitabineUrinary Bladder NeoplasmsAntimetabolites, AntineoplasticCell Line, TumorDeoxycytidineHumansAntimetabolites, AntineoplasticDeoxycytidineGemcitabinebladder cancercytotoxicitygemcitabinemathematical model

Identifiers

PMID37768422
OpenAlexW4387114390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.